MediWound Ltd. Files May 2024 Report on Form 6-K

TL;DR

MediWound Ltd. filed its May 2024 6-K, standard procedure for foreign issuers.

AI Summary

MediWound Ltd. filed a Form 6-K on May 29, 2024, reporting on its activities for the month of May 2024. The company, incorporated in Israel, is a foreign private issuer and files its annual reports on Form 20-F. Its principal executive offices are located at 42 Hayarkon Street, Yavne, Israel.

Why It Matters

This filing provides an update on MediWound Ltd.'s ongoing activities as a foreign private issuer, which is important for investors tracking the company's regulatory compliance and operational status.

Risk Assessment

Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain new financial information or significant business developments.

Key Players & Entities

• MediWound Ltd. (company) — Registrant
• May 2024 (date) — Reporting period
• May 29, 2024 (date) — Filing date
• 42 Hayarkon Street Yavne, 8122745 Israel (address) — Principal executive offices

FAQ

Filing Documents

• zk2431528.htm (6-K) — 11KB
• exhibit_99-1.htm (EX-99.1) — 288KB
• image00001.jpg (GRAPHIC) — 3KB
• 0001178913-24-001875.txt ( ) — 304KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): EXPLANATORY NOTE On May 29, 2024, MediWound Ltd. (the "Company") issued a press release entitled "MediWound Reports First Quarter 2024 Financial Results and Provides Company Update". A copy of this press release is attached to this Form 6-K as Exhibit 99.1. The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company), is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023 (Registration Nos. 333-265203 and 333-268297, respectively). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: May 29, 2024 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer 3 EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit 99.1 Description Press release dated May 29, 2024 titled "MediWound Reports First Quarter Financial Results and Provides Company Update". 4

View Full Filing

View this 6-K filing on SEC EDGAR